Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet-derived growth factor receptor alpha and Platelet-derived growth factor receptor beta are cell-surface receptors with intrinsic tyrosine kinase activity, each encoded by separate genes. They bind PDGF isoforms (homodimers and heterodimers of PDGF-A, PDGF-B, PDGF-C, PDGF-D), causing receptor homo- or heterodimerization. Ligand binding leads to activation via transphosphorylation of intracellular tyrosines, initiating downstream signaling pathways that control cell proliferation, migration, and differentiation. Aberrant activation is implicated in cancer, fibrotic, and proliferative diseases. They are well-established therapeutic targets for tyrosine kinase inhibitors.
Tyrosine kinase inhibition: drugs bind to the receptor’s kinase domain, preventing autophosphorylation and signal transduction
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet-derived growth factor receptor alpha; Platelet-derived growth factor receptor beta (PDGFRA; PDGFRB).